journal article·2012-09

Synergistic treatment of ovarian cancer by co-delivery of survivin shRNA and paclitaxel via supramolecular micellar assembly

Qinglian Hu, Wen Li, Xiurong Hu, Qida Hu, Jie Shen, Xue Jin, Jun Zhou, Guping Tang, Paul K. Chu

Biomaterials· Volume 33· Issue 27
Publisher page

Abstract

Non-viral gene-delivery platforms have been developed to co-deliver chemotherapeutics and siRNAs. The synergistic effects between shRNAs against survivin and Paclitaxel (PTX) using supramolecular micelles self-assembled from the host PEI-CyD (PC) composed of β-cyclodextrin (β-CyD) and polyethylenimine (PEI, Mw 600) and guest adamantine conjugated PTX (Ada-PTX) in combination cancer therapy are investigated. The Ada-PTX is encapsulated inside the core and shRNA sticks to the shell surface. The physicochemical properties of these supramolecular nanoparticles are favorable to cell uptake and intracellular trafficking. Moreover, PTX and shRNA simultaneously delivered to SKOV-3 cells lead to efficient reduction in the survivin and Bcl-2 expression as well as synergistic cell apoptotic induction in the in vitro study. In particular, co-delivery of survivin shRNA and PTX suppresses cancer growth more effectively than delivery of either paclitaxel or shRNA in ovarian cancer therapy.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (30)

Show source-provided references
1. RNAi therapeutics: principles, prospects and challenges10.1016/j.addr.2007.03.005 ↗
2. Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications10.1517/14728222.12.5.637 ↗
3. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance10.1016/j.drup.2011.01.003 ↗
4. Survivin: a new target for anti-cancer therapy10.1016/j.ctrv.2009.05.003 ↗
5. Targeting survivin in cancer therapy10.1517/14728222.12.4.463 ↗
6. The characteristics and performance of a multifunctional nanoassembly system for the co-delivery of docetaxel and iSur-pDNA in a mouse hepatocellular carcinoma model10.1016/j.biomaterials.2009.09.103 ↗
7. Tailoring nanostructured solid-lipid carriers for time-controlled intracellular siRNA kinetics to sustain RNAi-mediated chemosensitization10.1016/j.biomaterials.2010.12.029 ↗
8. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia10.1021/ja00738a045 ↗
9. Taxol stabilizes microtubules in mouse fibroblast cells10.1073/pnas.77.3.1561 ↗
10. Paclitaxel and its formulations10.1016/S0378-5173(01)00986-3 ↗
11. Advances of paclitaxel formulations based on nanosystem delivery technology10.2174/138955712800493924 ↗
12. Gold nanoparticles surface-functionalized with paclitaxel drug and biotin receptor as theranostic agents for cancer therapy10.1016/j.biomaterials.2011.09.064 ↗
13. Strategy for increasing drug solubility and efficacy through covalent attachment to polyvalent DNA-nanoparticle conjugates10.1021/nn201446c ↗
14. The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery10.1016/j.biomaterials.2011.01.038 ↗
15. A folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model10.1021/nn200739q ↗
16. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer10.1074/jbc.M110.125906 ↗
17. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells10.1002/smll.200900621 ↗
18. Simultaneous delivery of siRNA and paclitaxel via a “two-in-one” micelleplex promotes synergistic tumor suppression10.1021/nn103349h ↗
19. Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin10.1021/nn2013707 ↗
20. Co-delivery of anti-vascular endothelial growth factor siRNA and doxorubicin by multifunctional polymeric micelle for tumor growth suppression10.1002/jbm.a.33055 ↗
21. Cationic supramolecular nanoparticles for co-delivery of gene and anticancer drug10.1039/C1CC10721F ↗
22. In vivo treatment of tumors using host-guest conjugated nanoparticles functionalized with doxorubicin and therapeutic gene pTRAIL10.1016/j.biomaterials.2011.10.043 ↗
23. Cyclodextrin-based inclusion complexation bridging supramolecular chemistry and macromolecular self-assembly10.1039/c0cs00153h ↗
24. Low molecular weight polyethylenimines linked by beta-cyclodextrin for gene transfer into the nervous system10.1002/jgm.874 ↗
25. Effect of chemical functionalities in poly(amido amine)s for non-viral gene transfection10.1016/j.jconrel.2008.06.022 ↗
26. A system for stable expression of short interfering RNAs in mammalian cells10.1126/science.1068999 ↗
27. Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex10.1016/j.biomaterials.2010.02.030 ↗
28. Expression of survivin messenger RNA correlates with poor prognosis in patients with hepatocellular carcinoma10.1097/00019606-200203000-00007 ↗
29. Survivin modulates microtubule dynamics and nucleation throughout the cell cycle10.1091/mbc.e05-08-0723 ↗
30. Effects and mechanism of downregulation of survivin expression by RNA interference on proliferation and apoptosis of lung cancer cells10.3892/mmr.2012.755 ↗